Sensus Healthcare Achieves Record Growth in Superficial Radiotherapy Systems and Revenue

### Sensus Healthcare Reports Record Growth in Superficial Radiotherapy Systems

Sensus Healthcare, Inc., a pioneering medical device firm based in Boca Raton, Florida, announces impressive financial results for the fourth quarter and the year ending December 31, 2024. The company achieves revenues of $13.1 million in the fourth quarter, marking a 4% increase compared to the same period last year. For the entire year, Sensus generates $41.8 million in revenue, reflecting a substantial 71% growth year-over-year. This financial success is complemented by a net income of $1.5 million for the quarter, equating to $0.09 per diluted share, positioning Sensus for its fifth consecutive profitable quarter—a clear indicator of the company’s robust business model and market demand.

A significant highlight of the quarter is the record shipment of 39 superficial radiotherapy (SRT) systems, bringing the total number of systems shipped to 115 for the year. This represents an 18% increase in quarterly shipments and a remarkable 74% rise annually, showcasing Sensus's growing presence in the medical device sector. The company also expands its international footprint, shipping five systems abroad in Q4, totaling ten systems for the year. This expansion strategy not only illustrates Sensus's commitment to global market penetration but also reflects increasing recognition of the benefits of non-invasive treatment solutions.

Chairman and CEO Joe Sardano emphasizes the increasing adoption of SRT systems and expresses optimism about the company’s strategic direction, particularly regarding exclusive agreements with corporate accounts. This strategy is bolstered by new Fair Deal Agreement revenue-sharing programs, which Sensus expects will attract prospective customers in 2025. Sardano highlights the versatility of SRT technology, citing a recent sale to Pompano Veterinary Clinic. Additionally, Sensus is focused on innovation, preparing to re-submit the TDI 510(k) application in early 2025, aimed at further enhancing its product offerings and patient access to effective treatments.

In related developments, Sensus Healthcare ends the year with a robust cash position of $22.1 million and zero debt, providing a strong foundation for future growth initiatives. The company is well-positioned to leverage its financial health and innovative capabilities to enhance customer relationships and expand its market reach throughout 2025. The outlook for Sensus remains positive as it continues to drive advancements in non-invasive treatment technologies, aiming to improve patient outcomes and bolster its competitive edge in the healthcare industry.

As Sensus Healthcare moves forward, the emphasis on strategic partnerships and ongoing product innovation is expected to propel the company to new heights, reinforcing its role as a leader in the medical device arena, particularly in superficial radiotherapy solutions.